Advertisement

Topics

A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

2018-02-21 19:15:12 | BioPortfolio

Published on BioPortfolio: 2018-02-21T19:15:12-0500

Clinical Trials [1470 Associated Clinical Trials listed on BioPortfolio]

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus n...

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease pr...

Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer

This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer. Patients will be randomiz...

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced breast cancer whose disease has failed prior taxane-based tre...

PubMed Articles [925 Associated PubMed Articles listed on BioPortfolio]

Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.

A novel PEG-cRGD-conjugated irinotecan derivative BGC0222 was designed and synthesized as antitumor agent. Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiprol...

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma ...

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.

Nivolumab, an anti-PD-1 antibody, has been shown to be effective in many cancers, such as malignant melanoma and lung cancer; however, nivolumab therapy can result in pseudoprogression. Diffuse alveol...

Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.

Immune Checkpoint Blockade Is Active in Melanoma Brain Metastases.

Treatment with nivolumab alone or nivolumab plus ipilimumab achieves intracranial responses.

Medical and Biotech [MESH] Definitions

Frequent URINATION at night that interrupts sleep. It is often associated with outflow obstruction, DIABETES MELLITUS, or bladder inflammation (CYSTITIS).

A genus of intestinal parasite worms which includes one of the most important hookworms of man, NECATOR AMERICANUS. The only other known species, N. suillus, has been recovered from pigs.

A genus of ascomycetous fungi in the family Nectriaceae, order HYPOCREALES. They are found as saprophytes on decaying wood or parasites of trees. Anamorphs include FUSARIUM and Cylindrocarpon.

Sugar-rich liquid produced in plant glands called nectaries. It is either produced in flowers or other plant structures, providing a source of attraction for pollinating insects and animals, as well as being a nutrient source to animal mutualists which provide protection of plants against herbivores.

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

More From BioPortfolio on "A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial